Results 121 to 130 of about 44,917 (208)

FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. [PDF]

Cancer Res
Banerjee M, Zaytseva YY, Reusch EM, Napier DL, Hasani S, Rychahou P, Izumi T, Cheek DA, Li J, Flight RM, Moseley HNB, Weiss HL, McCulloch W, Evers BM, Gao T.   +14 more
europepmc   +1 more source

Association Between Irinotecan-Containing Regimens and Functional and Nutritional Impairment in Advanced Colorectal Cancer: An Exploratory PG-SGA Analysis. [PDF]

Cancers (Basel)
Guerrero-Martín J, Macias-Montero R, Macías-Gañán Y, Araujo-Blesa M, Paniagua-Vivas MS, Sánchez-Diestro LE.   +5 more
europepmc   +1 more source

Distinct safety profiles of liposomal and conventional irinotecan: insights from clinical experience and real-world data. [PDF]

Front Pharmacol
Shan H, Huang S, Du Q, Wang M.
europepmc   +1 more source

Elucidating the Solvent-Dependent Solvation and Structural Stability of Irinotecan: A Molecular Simulation Study. [PDF]

Chemphyschem
Bitabo MM, Mlowe S, Shadrack DM, Paluch AS, Paul L.   +4 more
europepmc   +1 more source

Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. [PDF]

Front Oncol
Lentz RW, Dominguez ATA, Balmaceda NB, Arcaroli JJ, Bagby SM, Binns CA, Smoots SG, Jackson MM, Macbeth M, Holmstoen T, Banerjee T, Whitty PA, Yi SS, Lieu CH, Messersmith WA, Pitts TM.   +15 more
europepmc   +1 more source

Safety and Efficacy of FOLFIRI-3 (Split-Dose Irinotecan) for Unresectable Colorectal Cancer: A Stratified Analysis Based on <i>UGT1A1</i> Gene Polymorphisms. [PDF]

Cancers (Basel)
Ohira G, Miyauchi H, Tochigi T, Maruyama T, Okada K, Hirata A, Ikeda Y, Hayano K, Maruyama M, Ishige T, Matsushita K, Shuto K.   +11 more
europepmc   +1 more source

Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study. [PDF]

Signal Transduct Target Ther
Yang W, Zhang J, Liang P, Qian Z, Wang D, Zhang W, Li B, Cui C, Zhong X, Wu G, Sun Y.   +10 more
europepmc   +1 more source

A case report of advanced pancreatic cancer patient demonstrating remarkable efficacy with liposomal irinotecan after failure of multiple-line therapies. [PDF]

Front Oncol
Yu S, Zhu H.
europepmc   +1 more source

Is FOLFIRINOX more effective than gemcitabine plus nab-paclitaxel in pancreatic adenocarcinoma? -a decade of debate! [PDF]

J Gastrointest Oncol
Babiker HM.
europepmc   +1 more source

Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. [PDF]

Lancet Reg Health Eur
Peeters SLJ, Heersche N, Böhm D, Böhringer S, Guiljam R, Hulshof EC, de Man FM, de With M, Joosse M, Oomens G, Wu QY, Osman A, Bins S, van Hellemond IEG, Haberkorn BCM, Verschoor AJ, Wumkes ML, van Schaik RHN, Thijs AM, Gelderblom H, Guchelaar HJ, Mathijssen RHJ, Deenen MJ.   +22 more
europepmc   +1 more source